CORALVILLE, Iowa, Dec. 5, 2012 /PRNewswire/ -- CIVCO Medical Solutions is pleased to announce two key management appointments for its Multi-Modality Imaging and Radiation Oncology business units, designed to strengthen the company and position each division for long-term success.
Robin Therme has been promoted to senior vice president and general manager of CIVCO's Multi-Modality Imaging (MMI) business unit. Therme has been with CIVCO for over 20 years, most recently serving as senior vice president of sales and marketing. She has fulfilled a variety of leadership roles throughout the company, including sales, marketing, product development and management as well as business development. She holds a Masters of Business Administration from the University of Iowa and a Bachelor of Arts in communications from Iowa Wesleyan College.
"Robin has led her team in consistent growth of the MMI business and this appointment recognizes the outstanding contribution Robin has made to CIVCO's success," said Charles Klasson, CIVCO's President.Nat Geissel will lead CIVCO's Radiation Oncology (RO) business unit as senior vice president and general manager. Geissel joined CIVCO in June 2012 as vice president of product line management and marketing and quickly showed the leadership needed to execute RO's strategic plan. Geissel came to CIVCO after a distinguished career in medical imaging, software and medical device businesses. He was previously senior director, cardiology, for Cerner Corporation, a leading electronic medical record provider based in Kansas City, Mo. Prior to that, he held leadership positions with Sirtex Medical Inc., an oncology-based medical device company, and DMS Health Technologies, a worldwide distributor of patient monitoring and medical imaging equipment. Geissel holds a Bachelor of Science from University of Iowa. "Nat brings with him a great depth of knowledge and leadership experience in medical imaging equipment and devices, cancer therapy products and health care IT," Klasson said. "We look forward to Nat contributing to our radiation oncology business unit's success."